Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Pipeline Review, H1 2016', provides in depth analysis on Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted pipeline therapeutics. 

The report provides comprehensive information on the Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99)
- The report reviews Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) Overview 7
Therapeutics Development 8
Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Products under Development by Stage of Development 8
Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Products under Development by Therapy Area 9
Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Products under Development by Indication 10
Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Products under Development by Companies 13
Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Products under Development by Universities/Institutes 15
Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Companies Involved in Therapeutics Development 22
Advinus Therapeutics Ltd. 22
Johnson & Johnson 23
MAKScientific, LLC 24
Midatech Pharma US Inc. 25
Sigma-Tau S.p.A. 26
Takeda Pharmaceutical Company Limited 27
Zynerba Pharmaceuticals, Inc. 28
Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Drug Profiles 29
AM-3506 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
AM-5206 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
IPI-940 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
JNJ-40413269 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
KRN-5500 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecule to Inhibit FAAH for Chemotherapy Induced Neuropathic Pain - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecule to Inhibit FAAH for Pain - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules to Inhibit COX and FAAH for Oncology, Immunology and CNS Disorders - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
ST-4070 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
URB-694 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
URB-937 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
ZYN-002 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Dormant Projects 45
Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Discontinued Products 47
Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Featured News & Press Releases 48
Apr 12, 2016: Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid 48
Feb 25, 2016: Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome 49
Jan 06, 2016: Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial 49
Oct 20, 2015: Zynerba Pharmaceuticals Initiates Phase 1 Clinical Trial for ZYN002 CBD Gel 50
Jun 16, 2014: DARA BioSciences' KRN5500 Granted Orphan Drug Designation by FDA for Treatment of Multiple Myeloma 50
Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA 51
Nov 29, 2012: Dara BioSciences Submits Orphan Drug Application For KRN5500 To FDA 51
May 09, 2012: Dara To Advance Development Of KRN5500 For Treatment Of Cancer And Neuropathic Pain 52
Oct 10, 2011: DARA BioSciences Announces KRN5500 Demonstrated Significant Decrease In Intensity Of Neuropathic Pain In Patients With Cancer 53
Sep 15, 2011: DARA BioSciences To Present Positive Results Of KRN5500 Phase II Study At 5th Annual Therapeutics Summit 54
Aug 18, 2011: DARA BioSciences Receives Fast Track Designation From FDA For KRN5500 For Treatment Of Chemotherapy-Induced Neuropathic Pain In Patients With Cancer 55
Jun 01, 2011: Infinity To Provide Update On IPI-940 55
Mar 29, 2011: DARA Reports Promising Findings From Phase II Study Of KRN5500 at ADEPT 56
Feb 01, 2011: DARA's KRN5500 Study Results Selected For Presentation By International Conference On Accelerating Development Of Enhanced Pain Treatments 57
Dec 14, 2010: DARA BioSciences Reports Positive Phase II Data Of KRN5500 In Neuropathic Pain 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Assessment by Monotherapy/Combination Products, H1 2016 17
Number of Products by Stage and Mechanism of Action, H1 2016 18
Number of Products by Stage and Route of Administration, H1 2016 20
Number of Products by Stage and Molecule Type, H1 2016 21
Pipeline by Advinus Therapeutics Ltd., H1 2016 22
Pipeline by Johnson & Johnson, H1 2016 23
Pipeline by MAKScientific, LLC, H1 2016 24
Pipeline by Midatech Pharma US Inc., H1 2016 25
Pipeline by Sigma-Tau S.p.A., H1 2016 26
Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 27
Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016 28
Dormant Projects, H1 2016 45
Dormant Projects (Contd..1), H1 2016 46
Discontinued Products, H1 2016 47